This chemical reduces the death marker PDL-1 and angiogenic factors and increases the expression of the immunoregulatory receptor FOXP3+, which is associated with a poor prognosis in many types of cancer due to the infiltration of T regulatory cells that prevent tumor destruction and increase the concentration of immune-related antitumoral cells, such as CD8+, CD4+, and neutrophils. Here, FOXP3 is linked to neoplasm.